938467-02-8

Basic information

• Product Name: 2,6-Dibromo-4-fluorobenzaldehyde
• Synonyms: 2,6-Dibromo-4-fluorobenzaldehyde;2,6-Difluoro-4-fluorobenzaldehyde
• CAS NO: 938467-02-8
• Molecular Formula: C₇H₃Br₂FO
• Molecular Weight: 281.9045232
• Mol File: 938467-02-8.mol

Chemical Properties

• Melting Point: 86.6-87.4 °C
• Boiling Point: 277.8±35.0 °C(Predicted)
• Appearance: /
• Density: 2.047±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,6-Dibromo-4-fluorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dibromo-4-fluorobenzaldehyde(938467-02-8)
• EPA Substance Registry System: 2,6-Dibromo-4-fluorobenzaldehyde(938467-02-8)

Safety Data

• Hazardous Substances Data: 938467-02-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dibromo-4-fluorobenzaldehyde is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable building block for the development of new drugs and medicinal compounds.
Used in Agricultural Chemical Industry:
2,6-Dibromo-4-fluorobenzaldehyde is also used in the production of agricultural chemicals, such as pesticides and herbicides. Its ability to form a wide range of organic compounds makes it a versatile component in the development of effective and targeted agricultural products.
Used in Organic Synthesis:
Due to its high reactivity, 2,6-Dibromo-4-fluorobenzaldehyde is commonly used as a building block in the synthesis of various organic compounds. Its unique structure allows for the formation of a wide range of products, making it a valuable asset in the field of organic chemistry.

Upstream product

• 62720-29-0 1,3-dibromo-5-fluoro-2-iodobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 1435-51-4 1,3-dibromo-5-fluorobenzene 
• 906649-94-3 2,6-dibromo-4-fluorotoluene 
• 404928-18-3 2,6-dibromo-4-fluoro-benzonitrile 
• 1068-55-9 isopropylmagnesium chloride 
• 920-39-8 isopropylmagnesium bromide 

Downstream Products

• 1057384-97-0 1-[9-(2-cyclopropylethoxy)-2-(2,6-dibromo-4-fluorophenyl)-1H-phenanthro[9,10-d]imidazol-9-yl]-2-methylpropan-2-ol 
• 1057384-97-0 C₃₀H₂₇Br₂FN₂O₂ 
• 1346675-25-9 2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)-4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1346674-69-8 (2,6-dibromo-4-fluorophenyl)methanol 
• 1346673-13-9 2-bromo-4-fluoro-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346673-38-8 4-Fluoro-2-(1-oxo-3,4,6,7,8,9-hexahydro-pyrazino[1,2-a]indol-2(1H)-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1433989-85-5 (R)-2-(5-(5-(3,4-Dimethylpiperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-fluoro-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1433989-93-5 (R)-2-(5-((5-(2,4-dimethylpiperazin-1-yl)pyridin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-fluoro-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346676-93-4 4-fluoro-2-(5-(5-(3-(fluoromethyl)-4-methylpiperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-3,4,6,7,8,9-hexa-hydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346671-86-0 2-(5-fluoro-3-(5-(5-(3-(fluoromethyl)-4-methylpiperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(hydroxymethyl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1433990-15-8 2-bromo-6-(7,7-difluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-fluorobenzyl Acetate 
• 1346674-62-1 2,6-dibromo-4-fluorobenzyl acetate 
• 1346677-00-6 (2-bromo-4-fluoro-6-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^2,7]trideca-1⁽⁹⁾,2⁽⁷⁾,3-trien-5-yl}phenyl)methyl acetate 
• 1433990-25-0 2-bromo-4-fluoro-6-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 

Relevant articles and documents

QUINOXALINE DERIVATIVES

The present invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties

In our continued effort to discover and develop best-in-class Bruton's tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compounds that improved upon the druglike properties of our previous chemical matter. Compounds exemplified by G-744 are highly potent, selective for Btk, metabolically stable, well tolerated, and efficacious in an animal model of arthritis.

BICYCLIC PIPERAZINE COMPOUNDS

Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.

Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors

Phenanthrene imidazoles 26 and 44 have been identified as novel potent, selective and orally active mPGES-1 inhibitors. These inhibitors are significantly more potent than the previously reported chlorophenanthrene imidazole 1 (MF63) with a human whole blood IC50 of 0.20 and 0.14 μM, respectively. It exhibited a significant analgesic effect in a guinea pig hyperalgesia model at oral doses as low as 14 mg/kg. Both active and selective mPGES-1 inhibitors (26 and 44) have a relatively distinct pharmacokinetic profile and are suitable for clinical development. Crown Copyright

A practical synthesis of m-prostaglandin E synthase-1 inhibitor MK-7285

(Chemical Equation Presented) A practical, kilogram-scale chromatography-free synthesis of mPGE synthase I inhibitor MK-7285 is described. The route features a convergent assembly of the core phenanthrene unit via amide-directed ortho-metalation and proxi